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STAT3 is a latent cytoplasmic transcription factor, activated by the interleukin-6 (IL-6) family of cytokines and growth factors. 4, 5 Upon receptor mediated activation, STAT3 is phosphorylated on a single tyrosine residue (Tyr-705) by Janus activated kinases. Phosphorylated STAT3 (pSTAT3) subsequently dimerizes and translocate into the nucleus, where it binds enhancer sequences of its target genes that control fundamental cellular processes, including proliferation, differentiation, survival, and immunity. [5] [6] [7] Aberrant constitutive activation of STAT3 is frequently associated with various human cancers including MB, where it plays a deleterious role via prolonged activation of its downstream targets, promoting tumor progression. 8 Activated STAT3 is known to bind MYC promoter, a master regulator of proliferation and induces expression of the MYC gene in cancers. 9 Both MYC and STAT3 are oncoproteins and function as a sequencespecific transcription factors, governing the regulation of target genes integral to tumorigenesis. 10 In addition, activated STAT3 in cancer cells is known to stimulate its own transcription causing an increase in unphosphorylated STAT3 that contributes to tumorigenesis by mechanisms different from phosphorylated STAT3. 11, 12 STAT3 transcriptional activity under normal conditions is transient and is tightly regulated by the action of its negative regulators, for example, Suppressor of cytokine signaling 3, Src-homology 2 domain (SH2)-containing phosphatase 2, and Protein Inhibitor of Activated STAT3 (PIAS3). 13, 14 Importantly, PIAS3, a key cellular inhibitor, has been reported to inhibit STAT3 phosphorylation and DNA binding activity, followed by the suppression of STAT3-mediated gene activation. In some cancer models, it was shown that loss of PIAS3 activity contributes to STAT3 activation and subsequent cancer cell proliferation. 15 Although, mechanisms of PIAS protein mediated regulation of transcription factors are well documented, 16 PIAS3 dysregulation in cancers is poorly understood, except, for few studies, that report it might be regulated by noncoding micro-RNAs. 17, 18 Structurally, STAT3 comprises six functional domains of which STAT3 NH2 terminal domain (NTD) is known to play an important role in promoting protein-protein interactions and formation of a stable STAT3 tetramer, required for enhanced transcription of its target genes. 19 199006-101 (Negative control A) were purchased from Exiqon A/S (Denmark). The LNA control and LNA-miR-21 power inhibitors were added directly into the cell culture media as recommended by the manufacturer.
| MTT assays
MB cells were plated at a density of 25 000-30 000 cells/well of a 96
well plate in the presence/absence of the inhibitors and MTT assays were performed followed manufacturer's protocol (ATCC 30-1010 K).
Briefly, cells in 96-well plates were treated with a S3-NTDi at a concentration/time mentioned in figure/legends. Next day, 10 µL of MTT solution was added in each well and after 4 h of incubation at 37°C, 100 µL detergent was added to solubilize the cells at room temperature for overnight in the dark. The intensity of the color developed was determined at a 570 nm wavelength using a plate reader (Biotek, Winooski, VT). 
| Cell cycle analysis

| Apoptosis assays
The ability of S3-NTDi to induce apoptosis in MB cell lines were determined using an Annexin V-FITC double staining kit (cat #130-092-052, MACS, Auburn, CA) and following manufacturer's instruction. 
| Western blot analysis
| Colony assay
MB cells treated with S3-NTDi overnight, were reseeded at a very low density (∼500 cells/well in a 6-well plate). Cells were allowed to grow in normal medium for 2 weeks, prior to fixing with formaldehyde and staining of colonies with crystal violet solution.
| Chromatin immunoprecipitation (ChIP) assay
S3-NTDi treated and untreated MB cells were protein-protein crosslinked with Disuccinimidyl glutarate (DSG), followed by protein-DNA cross-linked with formaldehyde, as described previously. 26 Cells were then lysed and sheared chromatin were immunoprecipitated with either STAT3 Ab or IgG, following instructions from Pierce Magnetic ChIP Kit (#26157). Quantitative genomic PCR was performed in QuantStudio 3 Real-Time PCR System, using human Bcl-2 promoter and CCND1 promoter primers (#12924, #12531) from Cell Signaling.
Data were corrected for variations in input and expressed as fold change relative to IgG controls.
| Confocal microscopy
MB cells grown on cover slips were treated with inhibitors as described in figure/legends. Cells were stimulated with IL-6/sIL-6Rα prior to fixation and immunofluorescence staining as described previously. 27 Primary antibodies p-Tyr705 STAT3 (cell signaling Ab #9145, used at dilution 1:50) or PIAS3 (Santa Cruz Ab, sc-14017 used at dilution 1:100) were used. Confocal images were taken with a Zeiss LSM 5
Pascal confocal microscope (Carl Zeiss, Oberkochen, Germany) using a 63X objective with a numerical aperture (NA) of 1.4 and appropriate filters in UNMC advanced confocal microscopy facility. 
| Immunohistochemistry (IHC)
MB
| Statistical analysis
The results are representative of three independent experiments and are expressed as the means ± SD, as indicated. Statistical analysis of the data was performed using the Student's t-test. 
| S3-NTDi impedes cell migration and colony formation
To investigate whether S3-NTDi decreased cancer cell mobility, we conducted in vitro wound healing assays, as many cellular processes of tumor metastasis replicate wound healing steps. 30 Here, we artificially created a gap by a "scratch" in HD-MB03 cell monolayers and serial images of cell migrations were taken over the next 72 h. We observed that non-treated (NT) control cells migrated to fill the gap area completely within 48 h ( Figure 3A) , whereas, S3-NTDi treated cells took significantly longer time to fill only 15% of the scratch area ( Figure 3B ). This indicates that S3-NTDi profoundly affects the migratory properties of MB cells and likely their ability to metastasize.
We next determined the ability of HD-MB03 cells to sustain proliferation after pretreatment with S3-NTDi, by a colony formation assay ( Figure 3C ). S3-NTDi significantly reduced the number of viable colonies as compared to no treatment control, indicating that S3-NTDi affects the ability of single cells to reproduce and to form large, visible colonies.
| Role of STAT3-NTD on IL-6 mediated EMT
IL-6 is a pleiotropic cytokine which is elevated in many types of cancer, enhancing cancer cell proliferation and inducing EMT, a phenotypic conversion prerequisite for tumor invasion and metastasis. 31 
| S3-NTDi affects MB-sphere formation and marker gene expression
Induction of EMT in cancer cells plays an important role in promoting self-renewing cancer "stem cell" enrichment and giving rise to tumor spheres. 33 Here, we examined MB-sphere formation in HD-MB03 and DAOY cells when grown in serum free media and in ultra-low adherent tissue culture plates. 34 We found that both DAOY and HD-MB03 cells form varied numbers and sizes of MB-spheres ( Figure 4A ), whereas, in the presence of S3-NTDi the number of MB-spheres significantly 
| DISCUSSIONS
Human Group3 MB is characterized by amplification of the MYC oncogene, isochromosome 17q and large cell anaplastic histology and have the worst prognosis among all MB sub-types. 41 Reappearance of tumors after surgical resection is common in MB and often confers resistant to chemotherapy and radiation. Therefore, development of novel therapeutic approaches, by delineating specific molecular pathways that leads to aggressive tumor growth and chemoresistance are highly desirable. 2, 42 STAT3 is constitutively activated in human solid tumors, due to the paracrine effects of secreted IL-6 and growth factors from the tumor microenvironment. 43 Out of six functional domains of STAT3, STAT3-NTD is highly conserved between species and does not share homology with any other proteins and therefore, STAT3-NTD inhibitors offer minimum chances of off-target effects, compared to its other domains. 44 Moreover, STAT3-NTD can fold independently and can undergo several post-translational modifications (PTM), required for protein-protein interactions and recruitment of transcriptional machinery. Previously, we have shown that STAT3-NTD undergoes PTM, by acetylation and by monoubiquitination, required for nuclear complex formation with several transcriptional regulators. 24, 25, [45] [46] [47] For these reasons, we have targeted STAT3-NTD in MB by using a cell permeable peptide inhibitor that was previously been shown effective on breast and prostate cancer cells. 22, 23 We provided evidence for the first time that STAT3-NTD inhibition has profound cytotoxic effects in pediatric MB cell lines, derived from high-risk SHH-TP53-mutated (DAOY) and MYC-amplified Non-WNT/SHH tumors (HDMB and D341). 29 Our data showed that S3-NTDi induces apoptotic cell death ( Figures 1C and 1D We have also shown that suppression of the STAT3-NTD, inhibited expression of oncogene MYC (Figures 2A and 2B ), a master regulator of proliferation and oncomiR-21 that modulates expression of key regulatory protein (PIAS3) in the STAT3 signal transduction pathway ( Figure 4D ).
Tumor cell migration and invasion is the first step of cancer metastasis, enabled by EMT. 48 In our study, we showed that S3-NTDi reduces increased mobility of MB cells, in a wound-healing assay ( Figure 3A) and downregulates IL-6 induced TWIST and SNAIL One striking observation of this study is that, simultaneous treatment of S3-NTDi and cisplatin synergistically killed MB cells by 
